hrp0092p1-430 | Thyroid (2) | ESPE2019

Clinical Characteristics and Long-Term Follow-Up of Patients with Congenital Hypothyroidism (CH) due to Thyroid Peroxidase (TPO) Gene Mutations

Tobias Leraz , Almagor Tal , Admoni Osnat , Khayat Morad , Elias-Assad Gadhir , Almashanu Shlomo , Tenenbaum-Rakover Yardena

Backround: Hereditary inborn errors of thyroid hormone synthesis account for 10-15% of congenital hypothyroidism (CH). Thyroid peroxidase (TPO) deficiency is the most common enzymatic defect with a frequency of 50-90%.Aim: In the present study our objective was to characterize the long-term clinical outcome in patients with TPO deficiency and to assess the association between development of multinodular goiter (M...

hrp0089p3-p043 | Bone, Growth Plate & Mineral Metabolism P3 | ESPE2018

Low Level of Vitamin D in Children Increases the Risk of Bone Fractures

Nicolas Georges , Hoyek Fady , Assaf Elias , Abi Fares Georges , Akiki Simon

Introduction: The physiological process by which vitamin D regulates calcium and phosphorus metabolism, the major mineral constituents of bone tissue, is by far very well understood. However, the clinical implementation of vitamin D deficiency on bone fragility in childhood remains controversial.Objective: The aim of this case-control study is to investigate the prevalence of vitamin D deficiency among Lebanese children who experienced a ‘low-energy...

hrp0089p2-p404 | Thyroid P2 | ESPE2018

Hearing Loss Among Patients with Congenital Hypothyroidism

Almagor Tal , Nachtigal Dan , Sharoni Zohara , Elias-Assad Ghadir , Hess Ora , Havazelet Gilad , Tenenbaum-Rakover Yardena

Background: A high rate of hearing impairment has been reported in patients with congenital hypothyroidism (CH). However, this association has only been explored in a few studies with inconclusive findings.Objectives: To assess the prevalence of hearing impairment among patients with CH and determine whether hearing impairment is related to delay in supplemental therapy, etiology of CH or other parameters.Methods: Audiometry was un...

hrp0095p1-318 | Growth and Syndromes | ESPE2022

The molecular study of Ras/MAPK pathway and treatment of short stature in Noonan syndrome

Castro-Feijóo Lidia , Cabanas Rodríguez Paloma , E Heredia Ramírez Claudia , Martínez Isabel , López Abel Bernardo , Eiris Puñal Jesús , Barros Angueira Francisco , Loidi Lourdes , Barreiro Conde Jesús

Mutations in genes of the RAS/MAPK signalling pathway have been shown to cause several syndromes characterized by dysmorphic features, growth retardation, cognitive impairment, heart disease and cutaneous abnormalities. The GHrh treatment has been used to improve growth in children with Noonan syndrome.Material and methods: 201 cases of patients referred with clinical suspicion of S. Noonan and other RASopathies was studied. Analysis of ...

hrp0095p1-316 | Growth and Syndromes | ESPE2022

Curve matching to predict future growth in patients receiving recombinant human growth hormone: an interpretable and explainable method using big data

van Dommelen Paula , Arnaud Lilian , Koledova Ekaterina

Background: Prediction models demonstrate potential in predicting growth in patients receiving recombinant human growth hormone (r-hGH) for growth disorders. However, considerable information from patients is needed to calculate a predicted growth curve. The curve matching technique only requires height data. This technique identifies growth curves that are similar (matched) among real-world patients within a database. The growth curves of these ‘matched...

hrp0092p1-220 | GH and IGFs (1) | ESPE2019

Real-World Data From Electronic Monitoring of Adherence to Growth Hormone Treatment in Children with Growth Disorders: A Descriptive Analysis

Koledova Ekaterina , Tornincasa Vincenzo , van Dommelen Paula

Poor adherence to long-term growth hormone (GH) treatment can lead to suboptimal clinical outcomes. The easypod™ connect eHealth platform enables healthcare professionals to obtain an accurate picture of real-world adherence by allowing patients to transmit adherence data to a database. Our aims were to assess adherence to r-hGH (Saizen, Merck KGaA, Darmstadt, Germany) treatment with the easypod connect platform in children from treatment start to 48 months and to investi...

hrp0097fc11.6 | GH and IGFs | ESPE2023

Longitudinal analysis of the risk of brain tumour recurrence or progression in relation to the timing of commencement of growth hormone replacement therapy.

Paula Gonzalez-Mereles Ana , Gan Hoong-Wei

Introduction: Growth hormone deficiency (GHD) is the most frequent endocrine deficit in childhood survivors of brain tumours. However, there is insufficient evidence to guide the timing of growth hormone replacement (GHR). At Great Ormond Street Hospital timing is based on clinical need rather than in relation to oncological treatment. Therefore, sufficient variability in GHR timing is available to analyze its effect on tumour progression and recurrence.<p...

hrp0089p1-p202 | Pituitary, Neuroendocrinology and Puberty P1 | ESPE2018

Long-acting Octeotride Treatment in Children with Neurofibromatosis Type 1 - Optic Pathway Tumors and Growth Hormone Excess

Guiraldo Paula Ximena Molina , Hernandez Hector Salvador , Bartomeu Joan Prat , Paula Casano Sancho

Introduction: Growth hormone excess (GHE) in children with neurofibromatosis type 1 (NF-1) has been reported in some sporadic cases. Whether GHE stimulates progressive optic pathway glioma (OPG) growth is of concern. The prevalence of GHE in NF-1 has not been described and the scheme treatment has not been well characterized.Objective: To describe in children with NF-1/OPG and GH excess the treatment regimen and long term response to long- acting octeotr...

hrp0095p1-194 | Thyroid | ESPE2022

Response to initial treatment in a pediatric cohort of patients with papillary thyroid cancer (PTC): changes after 3 years of follow up

Papendieck Patricia , Eugenia Masnata Maria , Gabriela Ballerini Maria , Medin Martin , Elias Eugenia , Mateos Fernanda , Bergada Ignacio , Elena Chiesa Ana

Background: Childhood onset PTC has a more aggressive presentation but no overall increase in mortality compared to adults.Objective: To characterize a pediatric cohort with PTC at diagnosis using the American Thyroid Association (ATA) Initial Risk Stratification (IRS) and to evaluate the response to initial treatment until 3 years based on the modified ATA Dynamic Risk Stratification (DRS) for adults.<p class="abste...

hrp0092p1-221 | GH and IGFs (1) | ESPE2019

Individual Patterns of Objectively Measured Adherence to Growth Hormone Treatment and its Effect on Growth in Prepubertal Children with Growth Hormone Deficiency

van Dommelen Paula , Wit Jan M , Koledova Ekaterina

The easypod™ electromechanical injection in combination with the easypod Connect platform electronically records and transmits, in real time, accurate, objective records of the date, time and dose injected for patients receiving Growth Hormone (GH) for growth disorders, limiting the risk of misreporting and allowing physicians to accurately monitor patient behavior.The aim was to study individual patterns of adherence from start treatment up to 24 m...